{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:22:06Z","timestamp":1789590126892,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT230100138"],"award-info":[{"award-number":["FT230100138"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001039","name":"Neurosurgical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001785","name":"Flinders University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022513","name":"Tasmanian Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022712","name":"Mark Hughes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tips.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T16:08:30Z","timestamp":1745856510000},"page":"392-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Repurposing trifluoperazine for glioblastoma treatment"],"prefix":"10.1016","volume":"46","author":[{"given":"Manam Inushi","family":"De Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui K.","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-0852","authenticated-orcid":false,"given":"Cedric","family":"Bardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.03.005_bb0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.03.005_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC\u2013NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.03.005_bb0020","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41588-021-00927-7","article-title":"Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states","volume":"53","author":"Chaligne","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2025.03.005_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s43018-020-00154-9","article-title":"Gradient of developmental and injury response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity","volume":"2","author":"Richards","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tips.2025.03.005_bb0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canlet.2018.01.058","article-title":"Repurposing psychiatric drugs as anti-cancer agents","volume":"419","author":"Huang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tips.2025.03.005_bb0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.schres.2017.08.065","article-title":"The incidence rate of cancer in patients with schizophrenia: A meta-analysis of cohort studies","volume":"195","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tips.2025.03.005_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.schres.2004.06.016","article-title":"Cancer in schizophrenia: is the risk higher or lower?","volume":"73","author":"Grinshpoon","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tips.2025.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/cells8111453","article-title":"Targeting the stress-induced protein NUPR1 to treat pancreatic adenocarcinoma","volume":"8","author":"Santofimia-Castano","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.tips.2025.03.005_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1320621","article-title":"Repurposing phenothiazines for cancer therapy: compromising membrane integrity in cancer cells","volume":"13","author":"Mehrabi","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111692","article-title":"Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells","volume":"183","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.03.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf1332","article-title":"Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma","volume":"9","author":"Stringer","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.03.005_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-016-2337-0","article-title":"Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1\/2, p38 MAPK and caspase-3","volume":"132","author":"Li","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41419-017-0253-7","article-title":"The interactome and spatial redistribution feature of Ca2+ receptor protein calmodulin reveals a novel role in invadopodia-mediated invasion","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tips.2025.03.005_bb0075","doi-asserted-by":"crossref","first-page":"11085","DOI":"10.1073\/pnas.1920154117","article-title":"The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma","volume":"117","author":"Bhat","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.03.005_bb0080","first-page":"6636","article-title":"The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas","volume":"50","author":"Hait","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.03.005_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002800050449","article-title":"Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer","volume":"38","author":"Murren","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.005_bb0090","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.1988.6.5.880","article-title":"Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine \u2013 a phase-I\/II trial","volume":"6","author":"Miller","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13046-017-0588-z","article-title":"Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination","volume":"36","author":"Zhang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.03.005_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-16-0169-T","article-title":"Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP3R","volume":"16","author":"Kang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.03.005_bb0105","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/bloodadvances.2018015677","article-title":"A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia","volume":"2","author":"Aslostovar","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2025.03.005_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1320710","article-title":"Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial","volume":"13","author":"Pace","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0115","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","first-page":"3","article-title":"Schizophrenia and related psychoses","author":"Taylor","year":"2021"},{"key":"10.1016\/j.tips.2025.03.005_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/neuonc\/noae011","article-title":"Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going?","volume":"26","author":"Sloan","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2022.10.010","article-title":"Neuronal and tumourigenic boundaries of glioblastoma plasticity","volume":"9","author":"De Silva","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tips.2025.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/cdd.2014.31","article-title":"Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy","volume":"21","author":"Auffinger","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2025.03.005_bb0135","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1158\/1535-7163.MCT-15-0675","article-title":"Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model","volume":"15","author":"Lee","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.03.005_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1192\/apt.bp.109.006908","article-title":"Meet the relatives: a reintroduction to the clinical pharmacology of 'typical' antipsychotics (Part 1)","volume":"18","author":"Owens","year":"2012","journal-title":"Adv. Psychiatr. Treat."},{"key":"10.1016\/j.tips.2025.03.005_bb0145","article-title":"Trifluoperazine for schizophrenia","volume":"2004","author":"Marques","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2025.03.005_bb0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41568-023-00556-8","article-title":"The neural addiction of cancer","volume":"23","author":"Magnon","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2025.03.005_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0160","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0170","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.03.005_bb0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","article-title":"Autonomous rhythmic activity in glioma networks drives brain tumour growth","volume":"613","author":"Hausmann","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0180","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.03.005_bb0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0190","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1523\/JNEUROSCI.3532-16.2017","article-title":"Tweety-homolog 1 drives brain colonization of gliomas","volume":"37","author":"Jung","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2025.03.005_bb0195","article-title":"Trifluoperazine regulates blood\u2013brain barrier permeability via the MLCK\/p-MLC pathway to promote ischemic stroke recovery","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.tips.2025.03.005_bb0200","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/brain\/awz331","article-title":"Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema","volume":"142","author":"Herting","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.tips.2025.03.005_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12987-024-00590-0","article-title":"Blood\u2013brain barrier permeability increases with the differentiation of glioblastoma cells in vitro","volume":"21","author":"Digiovanni","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tips.2025.03.005_bb0210","doi-asserted-by":"crossref","first-page":"24776","DOI":"10.1074\/jbc.M110.202804","article-title":"Calmodulin mediates Fas-induced FADD-independent survival sgnaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK)","volume":"286","author":"Yuan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.03.005_bb0215","doi-asserted-by":"crossref","first-page":"25308","DOI":"10.18632\/oncotarget.4490","article-title":"Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer","volume":"6","author":"Yuan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2025.03.005_bb0220","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1002\/jcb.26848","article-title":"Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells","volume":"119","author":"Fancy","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2025.03.005_bb0225","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/jcb.25882","article-title":"Calmodulin binding to death receptor 5-mediated death-inducing signaling complex in breast cancer cells","volume":"118","author":"Fancy","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2025.03.005_bb0230","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jcb.29892","article-title":"Calmodulin\/CaMKII-gamma mediates prosurvival capability in apicidin-persistent hepatocellular carcinoma cells via ERK1\/2\/CREB\/c-fos signaling pathway","volume":"122","author":"Hsu","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2025.03.005_bb0235","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbrc.2020.01.073","article-title":"Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration","volume":"524","author":"Kang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2025.03.005_bb0240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tcb.2022.07.004","article-title":"Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications","volume":"33","author":"Zheng","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.tips.2025.03.005_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35020-3","article-title":"Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis","volume":"8","author":"Santofimia-Castano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.03.005_bb0250","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/15384047.2015.1046022","article-title":"The interplay between DNA repair and autophagy in cancer therapy","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tips.2025.03.005_bb0255","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/15548627.2017.1338556","article-title":"NUPR1 maintains autolysosomal efflux by activating SNAP25 transcription in cancer cells","volume":"14","author":"Mu","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.tips.2025.03.005_bb0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1620\/tjem.2022.J044","article-title":"Trifluoperazine synergistically potentiates bortezomib-induced anti-cancer effect in multiple myeloma via inhibiting P38 MAPK\/NUPR1","volume":"257","author":"Jing","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.tips.2025.03.005_bb0265","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/2211-5463.12960","article-title":"Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma","volume":"10","author":"Li","year":"2020","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.tips.2025.03.005_bb0270","first-page":"681","article-title":"Combination of AAV-mediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice","volume":"43","author":"Li","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tips.2025.03.005_bb0275","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.tips.2023.08.012","article-title":"Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors","volume":"44","author":"Scarpellini","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.03.005_bb0280","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41467-021-20904-2","article-title":"NUPR1 is a critical repressor of ferroptosis","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.03.005_bb0285","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.3390\/cancers13153670","article-title":"NUPR1: a critical regulator of the antioxidant system","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2025.03.005_bb0290","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-024-08285-0","article-title":"Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis","volume":"637","author":"Zhuang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.005_bb0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF00435836","article-title":"Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine","volume":"23","author":"Hait","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.005_bb0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2025.03.005_bb0305","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0310","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bbrc.2017.10.106","article-title":"A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth","volume":"494","author":"Pinheiro","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2025.03.005_bb0315","first-page":"3300","article-title":"Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44\/DOX drug-resistant glioma cell line","volume":"42","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.tips.2025.03.005_bb0320","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/dna.2017.3790","article-title":"Trifluoperazine activates FOXO1-related signals to inhibit tumor growth in hepatocellular carcinoma","volume":"36","author":"Jiang","year":"2017","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.tips.2025.03.005_bb0325","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0006-2952(94)90048-5","article-title":"Comparative-study of intracellular calcium and adenosine 3\u2032,5\u2032-cyclic-monophosphate levels in human breast-carcinoma cells sensitive or resistant to adriamycin(r) \u2013 contribution to reversion of chemoresistance","volume":"48","author":"Mestdagh","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.005_bb0330","first-page":"383","article-title":"Human sarcoma cell lines MES-SA and MES-SA\/Dx5 as a model for multidrug resistance modulators screening","volume":"25","author":"Wesolowska","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tips.2025.03.005_bb0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00873916","article-title":"Phase-II trial of doxorubicin and trifluoperazine in metastatic breast-cancer","volume":"11","author":"Budd","year":"1993","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.tips.2025.03.005_bb0340","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.tips.2025.03.005_bb0345","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12967-024-05501-3","article-title":"Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways","volume":"22","author":"Matarrese","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2025.03.005_bb0350","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2025.03.005_bb0355","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00004714-198910000-00005","article-title":"Trifluoperazine plasma levels and clinical response","volume":"9","author":"Janicak","year":"1989","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.03.005_bb0360","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2125.1981.tb01199.x","article-title":"Radioimmunoassay for trifluoperazine in human plasma","volume":"12","author":"Midha","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.005_bb0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0022-3565(25)28588-3","article-title":"Efflux of chlorpromazine and trifluoperazine from the rat brain","volume":"174","author":"Spano","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2025.03.005_bb0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0893-133X(95)00070-T","article-title":"Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat","volume":"13","author":"Aravagiri","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.03.005_bb0375","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tips.2025.03.005_bb0380","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41598-018-19413-y","article-title":"Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells","volume":"8","author":"Wen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.03.005_bb0385","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.03.005_bb0390","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","article-title":"Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.03.005_bb0395","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","article-title":"Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities","volume":"2","author":"Garofano","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tips.2025.03.005_bb0400","series-title":"StatPearls","article-title":"Ommaya reservoir","author":"Zubair","year":"2023"},{"key":"10.1016\/j.tips.2025.03.005_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200544010-00001","article-title":"Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis","volume":"44","author":"Fleischhack","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tips.2025.03.005_bb0410","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00165710","article-title":"Pharmacokinetics of intraventricular administration","volume":"1","author":"Collins","year":"1983","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.tips.2025.03.005_bb0415","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fneur.2014.00220","article-title":"Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients","volume":"5","author":"Dardis","year":"2014","journal-title":"Front. Neurol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:16:06Z","timestamp":1762251366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0165614725000458"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.03.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing trifluoperazine for glioblastoma treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}